Page 17 - 53-Peptic ulcer diseases (Loét dạ dày)

819.e2 References

49. Richter JM, Colditz GA, Huse DM, et al. Cimetidine and adverse 73. Malfertheiner P, Kirchner T, Kist M, et al. Helicobacter pylori eradi-
reactions: a meta-analysis of randomized clinical trials of short-term cation and gastric ulcer healing—comparison of three pantoprazole-
therapy. Am J Med 1989;87:278–84. based triple therapies. BYK Advanced Gastric Ulcer Study Group.
50. Garcia Rodriguez LA, Jick H. Risk of gynaecomastia associated Aliment Pharmacol Ther 2003;17:1125–35.
with cimetidine, omeprazole, and other anti-ulcer drugs. BMJ 74. Higuchi K, Fujiwara Y, Tominaga K, et al. Is eradication sufficient
1994;308:503–6. to heal gastric ulcers in patients infected with Helicobacter pylori?
51. Hansten PD. Drug interactions with anti-secretory agents. Aliment A randomized, controlled, prospective study. Aliment Pharmacol
Pharmacol Ther 1991;5:121–8. Ther 2003;17:111–7.
52. Robinson M, Horn J. Clinical pharmacology of proton pump in- 75. Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omepra-
hibitors: what the practising physician needs to know. Drugs zole with ranitidine for ulcers associated with non-steroidal an-
2003;63:2739–54. tiinflammatory drugs. Acid Suppression Trial: ranitidine versus
53. Zhang L, Mei Q, Li QS, et al. The effect of cytochrome P2C19 Omeprazole for NSAID-Associated Ulcer Treatment (ASTRO-
and interleukin-1 polymorphisms on H. pylori eradication rate of NAUT) study group. N Engl J Med 1998;338:719–26.
1-week triple therapy with omeprazole or rabeprazole, amoxycillin 76. Agrawal NM, Campbell DR, Safdi MA, et al. Superiority of lanso-
and clarithromycin in Chinese people. J Clin Pharm Ther 2010;35: prazole versus ranitidine in healing nonsteroidal antiinflammatory
713–22. drug-associated gastric ulcers: results of a double-blind, random-
54. Wolfe MM, Sachs G. Acid suppression: optimizing therapy for ized, multicenter study. NSAID-Associated Gastric Ulcer Study
gastroduodenal ulcer healing, gastroesophageal reflux disease, and Group. Arch Intern Med 2000;160:1455–61.
stress-related erosive syndrome. Gastroenterology 2000;118:S9–31. 77. Goldstein JL, Johanson JF, Hawkey CJ, et al. Clinical trial: healing
55. Vakil N. Prescribing proton pump inhibitors: is it time to pause and of NSAID-associated gastric ulcers in patients continuing NSAID
rethink? Drugs 2012;72:437–45. therapy—a randomized study comparing ranitidine with esomepra-
56. Lew EA. Pharmacokinetic concerns in the selection of anti-ulcer zole. Aliment Pharmacol Ther 2007;26:1101–11.
therapy. Aliment Pharmacol Ther 1999;13:11–6. 78. Roth S, Agrawal N, Mahowald M, et al. Misoprostol heals gastrodu-
57. Kwok CS, Loke YK. Meta-analysis: the effects of proton pump in- odenal injury in patients with rheumatoid arthritis receiving aspirin.
hibitors on cardiovascular events and mortality in patients receiving Arch Intern Med 1989;149:775–9.
clopidogrel. Aliment Pharmacol Ther 2010;31:810–23. 79. Hawkey CJ, Karrasch JA, Szezepanski L, et al. Omeprazole com-
58. Focks JJ, Brouwer MA, van Oijen MG, et al. Concomitant use of pared with misoprostol for ulcers associated with non-steroidal an-
clopidogrel and proton pump inhibitors: impact on platelet function tiinflammatory drugs: omeprazole versus Misoprostol for NSAID-
and clinical outcome—a systematic review. Heart 2013;99:520–7. Induced Ulcer Management (OMNIUM) Study Group. N Engl J
59. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or Med 1998;338:727–34.
without omeprazole in coronary artery disease. N Engl J Med 80. Kyaw MH, Otani K, Ching JYL, et al. Misoprostol heals small bow-
2010;363:1909–17. el ulcers in aspirin users with small bowel bleeding. Gastroenterol-
60. O’Donoghue ML, Braunwald E, Antman EM, et al. Pharmacody- ogy 2018;S0016–5085(18)34698–5.
namic effect and clinical efficacy of clopidogrel and prasugrel with 81. Taha AS, McCloskey C, McSkimming P, McConnachie A. Miso-
or without a proton-pump inhibitor: an analysis of two randomised prostol for small bowel ulcers in patients with obscure bleeding
trials. Lancet 2009;374:989–97. taking aspirin and non-steroidal anti-inflammatory drugs (MAS-
61. Targownik L. Discontinuing long-term PPI therapy: WHY, with TERS): a randomised, double-blind, placebo-controlled, phase 3
whom, and how? Am J Gastroenterol 2018;113:519–28. trial. Lancet Gastroenterol Hepatol 2018;3:469–76.
62. Hori Y, Imanishi A, Matsukawa J, et al. 1-[5-(2-Fluorophenyl)- 82. Lancaster-Smith MJ, Jaderberg ME, Jackson DA. Ranitidine in the
1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine treatment of nonsteroidal anti-inflammatory drug associated gastric
monofumarate (TAK-438), a novel and potent potassium-compet- and duodenal ulcers. Gut 1991;32:252–5.
itive acid blocker for the treatment of acid-related diseases. J Phar- 83. Singh G, Triadafilopoulus G. Epidemiology of NSAID-induced GI
macol Exp Ther 2010;335:231–8. complications. J Rheumatol 1999;26:18–24.
63. Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vo- 84. Rostom A, Wells G, Tugwell P, et al. Prevention of NSAID-in-
noprazan 20 mg compared with esomeprazole 20 mg or rabepra- duced gastroduodenal ulcers (Cochrane review). Cochrane Data-
zole 10 mg in healthy adult male subjects—a randomised open-label base Syst Rev 2000;4:CD002296.
cross-over study. Aliment Pharmacol Ther 2015;42:719–30. 85. Chan FK, Kyaw M, Tanigawa T, et al. Similar efficacy of proton-
64. Miwa H, Uedo N, Watari J, et al. Randomised clinical trial: efficacy pump inhibitors vs H2-receptor antagonists in reducing risk of up-
and safety of vonoprazan vs. lansoprazole in patients with gastric per gastrointestinal bleeding or ulcers in high-risk users of low-dose
or duodenal ulcers—results from two phase 3, non-inferiority ran- aspirin. Gastroenterology 2017;152:105–10.
domised controlled trials. Aliment Pharmacol Ther 2017;45:240–52. 86. Chan FK, Sung JJ, Ching JY, et al. Randomized trial of low-dose
65. Kawai T, Oda K, Funao N, et al. Vonoprazan prevents low-dose misoprostol and naproxen vs. nabumetone to prevent recurrent
aspirin-associated ulcer recurrence: randomised phase 3 study. Gut upper gastrointestinal haemorrhage in users of non-steroidal anti-
2018;67:1033–41. inflammatory drugs. Aliment Pharmacol Ther 2001;15:19–24.
66. Mizokami Y, Oda K, Funao N, et al. Vonoprazan prevents ulcer 87. Graham DY, Agrawal NM, Campbell DR, et al. Ulcer prevention in
recurrence during long-term NSAID therapy: randomised, lanso- long-term users of nonsteroidal anti-inflammatory drugs: results of a
prazole-controlled non-inferiority and single-blind extension study. double-blind, randomized, multicenter, active- and placebo-controlled
Gut 2018;67:1042–51. study of misoprostol vs lansoprazole. Arch Intern Med 2002;62:169–75.
67. McCarthy DM. Sucralfate. N Engl J Med 1991;325:1017–25. 88. Regula J, Butruk E, Dekkers CP, et al. Prevention of NSAID-as-
68. Wagstaff AJ, Benfield P, Monk JP. Colloidal bismuth subcitrate. A sociated gastrointestinal lesions: a comparison study pantoprazole
review of its pharmacodynamic and pharmacokinetic properties, and versus omeprazole. Am J Gastroenterol 2006;101:1747–55.
its therapeutic use in peptic ulcer disease. Drugs 1988;36:132–57. 89. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Effect of antise-
69. Walt RP. Misoprostol for the treatment of peptic ulcer and antiin- cretory drugs and nitrates on the risk of ulcer bleeding associated
flammatory-drug-induced gastroduodenal ulceration. N Engl J Med with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and
1992;327:1575–80. anticoagulants. Am J Gastroenterol 2007;102:507–15.
70. Chen MC, Amirian DA, Toomey M, et al. Prostanoid inhibition 90. Chan FK, To KF, Wu JC, et al. Eradication of Helicobacter pylori and
of canine parietal cells: mediation by the inhibitory guanosine tri- risk of peptic ulcers in patients starting long term treatment with
phosphate-binding protein of adenylate cyclase. Gastroenterology non-steroidal anti-inflammatory drugs: a randomized trial. Lancet
1988;94:1121–9. 2002;359:9–13.
71. Sung JJ, Chung SC, Ling TK, et al. Antibacterial treatment of 91. Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac
gastric ulcers associated with Helicobacter pylori. N Engl J Med and omeprazole in reducing the risk of recurrent ulcer bleeding in
1995;332:139–42. patients with arthritis. N Engl J Med 2002;347:2104–10.
72. Ford AC, Delaney BC, Forman D, et al. Eradication therapy in He- 92. Rostom A, Muir K, Dube C, et al. Gastrointestinal safety of cyclo-
licobacter pylori positive peptic ulcer disease: systematic review and oxygenase-2 inhibitors: a Cochrane collaboration systematic review.
economic analysis. Am J Gastroenterol 2004;99:1833–55. Clin Gastroenterol Hepatol 2007;5:818–28.